219 related articles for article (PubMed ID: 35917568)
21. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract][Full Text] [Related]
22. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
23. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
24. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
25. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.
Du L; Liu W; Pichiorri F; Rosen ST
Cancer Gene Ther; 2023 Apr; 30(4):567-574. PubMed ID: 35338347
[TBL] [Abstract][Full Text] [Related]
26. Diversification of SUMO-activating enzyme in Arabidopsis: implications in SUMO conjugation.
Castaño-Miquel L; Seguí J; Manrique S; Teixeira I; Carretero-Paulet L; Atencio F; Lois LM
Mol Plant; 2013 Sep; 6(5):1646-60. PubMed ID: 23482370
[TBL] [Abstract][Full Text] [Related]
27. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
28. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
Bergaggio E; Riganti C; Garaffo G; Vitale N; Mereu E; Bandini C; Pellegrino E; Pullano V; Omedè P; Todoerti K; Cascione L; Audrito V; Riccio A; Rossi A; Bertoni F; Deaglio S; Neri A; Palumbo A; Piva R
Blood; 2019 Jan; 133(2):156-167. PubMed ID: 30455381
[TBL] [Abstract][Full Text] [Related]
29. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
30. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
31. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor.
Tirard M; Almeida OF; Hutzler P; Melchior F; Michaelidis TM
Mol Cell Endocrinol; 2007 Mar; 268(1-2):20-9. PubMed ID: 17314004
[TBL] [Abstract][Full Text] [Related]
32. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
34. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
35. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
36. Regulation of REGγ cellular distribution and function by SUMO modification.
Wu Y; Wang L; Zhou P; Wang G; Zeng Y; Wang Y; Liu J; Zhang B; Liu S; Luo H; Li X
Cell Res; 2011 May; 21(5):807-16. PubMed ID: 21445096
[TBL] [Abstract][Full Text] [Related]
37. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
Zhang C; Wang X; Cheng R; Zhong Z
Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
[TBL] [Abstract][Full Text] [Related]
38. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
Manasanch EE; Korde N; Zingone A; Tageja N; Fernandez de Larrea C; Bhutani M; Wu P; Roschewski M; Landgren O
Leuk Lymphoma; 2014 Aug; 55(8):1707-14. PubMed ID: 24261677
[TBL] [Abstract][Full Text] [Related]
39. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
